Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celyad Sa ADR (NQ: CYAD ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, May 18, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Celyad Sa ADR Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) September 07, 2023 From Celyad Oncology SA Via GlobeNewswire Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) September 05, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights September 04, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders August 24, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology announces receipt of Nasdaq delisting notice May 15, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq May 05, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology reports first quarter 2023 financial results and recent business highlights May 05, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price April 24, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology announces receipt of Nasdaq notice April 04, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology appoints Georges Rawadi as its new CEO March 24, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology reports full year 2022 financial results and recent business highlights March 23, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology to announce full year 2022 financial results and host conference call March 17, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology announces non-cash impairment March 15, 2023 From Celyad Oncology SA Via GlobeNewswire REPEAT -- Celyad Oncology SA - Letter to Shareholders March 01, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology SA - Letter to Shareholders February 28, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01 February 09, 2023 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook February 03, 2023 From Celyad Oncology SA Via GlobeNewswire Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials January 19, 2023 EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 Product Safety Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property December 21, 2022 From Celyad Oncology SA Via GlobeNewswire Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights November 10, 2022 From Celyad Oncology SA Via GlobeNewswire Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction September 20, 2022 From Cellistic Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.